Quarterly ResultMay 29, 2026, 08:51 AM
Vyome Reports Q1 Results, In-licenses JAK Inhibitors, Files for FDA Orphan Drug
AI Summary
Vyome Holdings, Inc. announced its first fiscal quarter 2026 financial results, reporting approximately $8.8 million in cash and cash equivalents and a net loss of $963,000. The company significantly advanced its pipeline by signing an agreement with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets, targeting a large global market. Additionally, Vyome made regulatory submissions to the FDA for Orphan Drug Designation status for its lead candidate VT-1953, which addresses malignant fungating wounds, and presented positive Phase 2 clinical data for VT-1953.
Key Highlights
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences, targeting a ~$57B global market.
- Submitted Orphan Drug Designation application to the FDA for VT-1953.
- Ended Q1 2026 with approximately $8.8 million in cash and cash equivalents.
- Raised approximately $5.29 million in gross proceeds through common share sales in January 2026.
- Reported a net loss of approximately $963,000 for the first quarter ended March 31, 2026.
- Total operating expenses for Q1 2026 were approximately $1.1 million.
- Presented positive VT-1953 Phase 2 clinical study data at the American Association for Cancer Research 2026.
Price Impact
More from HIND